Replies to post #104756 on Regen BioPharma Inc (RGBP)

[jeffryer1]

And at what point will that be? I'm finding it difficult to even guess, so I won't.

[Musical Shares]

At some point, a BP will decide that all the patents accumulated by rgbp are worth going after...

That's not how it works.

Patents are not what "Big Pharma" go after. It's pipeline is the value (called "pipeline valuation".)

Valuation of biotech's are different than the traditional "revenue generating" companies.

What is taught at most (the most prestigious of universities teach it through case studies and complex mathematical depths) MBA programs are the basic valuation multiples such as EV/EBITDA or P/E ratios.

However, valuation of non revenue generating biotech's will try and rely on valuation mulitiples such as EV/Invested research and development. These are what they call cost-based valuations.

Big Pharma doesn't buy patents. They buy clinical data.